PMID- 24460353
OWN - NLM
STAT- MEDLINE
DCOM- 20140916
LR  - 20201219
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 14
IP  - 12
DP  - 2013
TI  - Immunoregulatory function of HLA-G in gastric cancer.
PG  - 7681-4
AB  - BACKGROUND: Human leukocyte antigen (HLA)-G-positive gastric cancers are 
      associated with poor survival, but links with tumor escape mechanisms remain to 
      be determined. MATERIALS AND METHODS: We used immunohistochemistry to investigate 
      HLA-G expression, tumor infiltrating CD8+ T lymphocytes, and Treg cells in 52 
      gastric cancer patients. RESULTS: There were 29 cancer-related deaths during the 
      follow-up period. Kaplan-Meier analysis indicated that patients with 
      HLA-G-positive (n=16) primary tumors had a significantly poorer prognosis than 
      patients with HLA-G-negative tumors (n=36, p=0.008). The median survival time was 
      14 months and 47 months, respectively. Patients with high numbers of Tregs and 
      low numbers of CD8+T lymphocytes in the primary tumor had a poorer prognosis than 
      those with low numbers of Tregs and high numbers of CD8+T lymphocytes (p=0.034, 
      p=0.043). Multivariate Cox proportional hazard regression analysis showed that 
      HLA-G expression (hazard ratio: 2.662; 95% confidence interval: 1.242-5.723; 
      p=0.012) and stage (hazard ratio: 2.012;95% confidence interval: 1.112-3.715; 
      p=0.041) were independent unfavorable factors for patient survival. CONCLUSIONS: 
      We found a significant positive correlation between HLA-G expression and the 
      number of tumor infiltrating Tregs (p=0.01) and a negative correlation with the 
      number of CD8+T lymphocytes (p=0.041). HLA-G may protect gastric cancer cells 
      from cytolysis by inducing Foxp3+Treg lymphocytes and suppressing CD8+T 
      lymphocytes.
FAU - Tuncel, Tolga
AU  - Tuncel T
AD  - Department of Medical Oncology, Gata Haydarpasa Training Hospital, Istanbul, 
      Turkey E-mail : dr_tolgatuncel@hotmail.com.
FAU - Karagoz, Bulent
AU  - Karagoz B
FAU - Haholu, Aptullah
AU  - Haholu A
FAU - Ozgun, Alpaslan
AU  - Ozgun A
FAU - Emirzeoglu, Levent
AU  - Emirzeoglu L
FAU - Bilgi, Oguz
AU  - Bilgi O
FAU - Kandemir, Emin Gokhan
AU  - Kandemir EG
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-G Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Female
MH  - Follow-Up Studies
MH  - HLA-G Antigens/immunology/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Prognosis
MH  - Stomach Neoplasms/*immunology/metabolism/mortality/pathology
MH  - Survival Rate
MH  - T-Lymphocytes, Regulatory/*immunology
EDAT- 2014/01/28 06:00
MHDA- 2014/09/17 06:00
CRDT- 2014/01/28 06:00
PHST- 2014/01/28 06:00 [entrez]
PHST- 2014/01/28 06:00 [pubmed]
PHST- 2014/09/17 06:00 [medline]
AID - 10.7314/apjcp.2013.14.12.7681 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2013;14(12):7681-4. doi: 10.7314/apjcp.2013.14.12.7681.